No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki-Reference-Cited by-同舟云学术

No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

Published:2020-10-23 Issue:12 Volume:111 Page:4490-4499
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci.

Author:

Toriyama Eo¹,Hata Tomoko²^ORCID,Yokota Ken‐ichi³,Chiwata Masahiko⁴,Kamijo Rena⁵,Hashimoto Miki¹,Taguchi Masataka⁶^ORCID,Horai Makiko⁶,Matsuo Masatoshi⁷,Matsuo Emi⁸,Takasaki Yumi⁹,Kawaguchi Yasuhisa¹⁰,Itonaga Hidehiro⁶,Sato Shinya⁶,Ando Koji²,Sawayama Yasushi⁶,Taguchi Jun¹¹,Imaizumi Yoshitaka⁶^ORCID,Tsushima Hideki⁷,Jo Tatsuro¹¹,Yoshida Shinichiro⁴,Moriuchi Yukiyoshi⁵,Miyazaki Yasushi¹²

Affiliation:

1. Department of Hematology Atomic Bomb Disease and Hibakusha Medicine Unit Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

2. Department of Hematology Atomic Bomb Disease and Hibakusha Medicine Unit Atomic Bomb Disease Institute Nagasaki University Nagasaki Japan

3. Biostatistics Section Division of Scientific Data Registry Atomic Bomb Disease Institute Nagasaki University Nagasaki Japan

4. Department of Hematology National Hospital Organization Nagasaki Medical Center Ohmura Japan

5. Department of Hematology Sasebo City General Medical Center Sasebo Japan

6. Department of Hematology Nagasaki University Hospital Nagasaki Japan

7. Department of Hematology Nagasaki Harbor Medical Center Nagasaki Japan

8. Department of Hematology Japan Community Health Care Organization Isahaya General Hospital Isahaya Japan

9. Department of Internal Medicine Saint Francis Hospital Nagasaki Japan

10. Department of Internal Medicine National Hospital Organization Nagasaki Hospital Nagasaki Japan

11. Department of Hematology Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan

Funder

Ministry of Health

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14653

Reference28 articles.

1. Myelodysplastic Syndromes

2. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

3. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

4. Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

5. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

2. Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report;Leukemia Research Reports;2024

3. Five‐day versus 7‐day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial;Cancer;2022-10-08